PDL2 compounds
AssigneeIO Biotech ApS
InventorMads Hald Andersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.
Claims8
A method of treating cancer in a patient, wherein the cancer is characterized by the expression of programmed death ligand 2 (PDL2), the method comprising administering to the patient an effective amount of a peptide fragment of a human PDL2 protein of SEQ ID NO:
- 1, which fragment consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO:
- 1 and which comprises an amino acid sequence selected from SEQ ID NOs 11, 2, 4 and 12;
- or a pharmaceutically acceptable salt thereof;
- or a nucleic acid encoding said peptide fragment;
- or a vector comprising a nucleic acid encoding said peptide fragment.
Dependencies are inferred from the claim text.